Sunday - January 11, 2026

Category Archives: Pharmaceuticals & Biotech

Schizophrenia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Schizophrenia pipeline constitutes 55+ key companies continuously working towards developing 60+ Schizophrenia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.   … Continue reading →

Prostate Cancer Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Telix Pharma, Merck, Orion Pharma, Exelixis, Ipsen Pharma and Takeda, Pfizer

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Prostate Cancer pipeline constitutes 140+ key companies continuously working towards developing 150+ Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

HER2-Positive Breast Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, HER2-Positive Breast Cancer pipeline constitutes 50+ key companies continuously working towards developing 55+ HER2-Positive Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Axillary Hyperhidrosis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Botanix Pharma, Sound Surgical Tech, Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corp.

The Key Axillary Hyperhidrosis Companies in the market include – Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, … Continue reading →

Myasthenia Gravis Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant

The Key Myasthenia Gravis Companies in the market include – Alexion, AstraZeneca, Argenx, Novartis, Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others. DelveInsight’s “Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034″ … Continue reading →

Actinic Keratosis Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Actinic Keratosis Market Insights, Epidemiology, and Market Forecast- 2034′′ report offers an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU4 (Germany, Spain, Italy, France, … Continue reading →

Metastatic Prostate Cancer Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast- 2034′′ report offers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU4 (Germany, … Continue reading →

EGFR Inhibitors-Induced Skin Disorders Market Size in the 7MM is expected to increase at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast- 2034′′ report offers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United … Continue reading →

The Bigger Picture: SurgePays’ (NASDAQ: SURG) Distinct Wireless and Fintech Platform-Becoming Dominant Play w/ SURG, ACON, ONDS, JTAI

As wireless connectivity, digital payments, and in-store commerce continue to converge, SurgePays (NASDAQ: SURG) is gaining attention not as a niche prepaid provider, but as a vertically integrated platform positioned across multiple high-value segments of the U.S. economy. The company’s … Continue reading →